HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory.
Cancer vaccine
E7
HPV 16 RNA-LPX
HPV16-positive malignancies
T cell memory
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
07
03
2019
revised:
04
06
2019
accepted:
04
06
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
21
8
2019
Statut:
epublish
Résumé
HPV16 infections are associated with a variety of cancers and there is compelling evidence that the transforming activity of HPV16 critically depends on the expression of the viral oncoproteins E6 and E7. Therapeutic cancer vaccines capable of generating durable and specific immunity against these HPV16 antigens hold great promise to achieve long-term disease control. Here we show in mice that HPV16 E7 RNA-LPX, an intravenously administered cancer vaccine based on immuno-pharmacologically optimized antigen-encoding mRNA, efficiently primes and expands antigen-specific effector and memory CD8
Identifiants
pubmed: 31428528
doi: 10.1080/2162402X.2019.1629259
pii: 1629259
pmc: PMC6685602
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e1629259Références
Gene Ther. 2000 May;7(9):726-33
pubmed: 10822298
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
J Immunol. 2002 Jul 1;169(1):350-8
pubmed: 12077264
Blood. 2006 Dec 15;108(13):4009-17
pubmed: 16940422
Nat Protoc. 2007;2(9):2049-56
pubmed: 17853860
J Immunol. 2008 Jan 1;180(1):309-18
pubmed: 18097032
IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636
pubmed: 18354839
Clin Cancer Res. 2008 May 15;14(10):3185-92
pubmed: 18483387
Lancet. 2008 May 17;371(9625):1695-709
pubmed: 18486742
Cancer Immunol Immunother. 2009 May;58(5):737-48
pubmed: 18815785
Cancer Res. 2008 Oct 15;68(20):8437-45
pubmed: 18922917
N Engl J Med. 2009 Nov 5;361(19):1838-47
pubmed: 19890126
Gene Ther. 2010 Aug;17(8):961-71
pubmed: 20410931
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Head Neck Oncol. 2010 Jun 29;2:15
pubmed: 20587061
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Cancer Immunol Immunother. 2012 Aug;61(8):1307-17
pubmed: 22527249
Cancer Res. 2013 Jan 1;73(1):128-38
pubmed: 23135914
Sci Transl Med. 2013 Feb 13;5(172):172ra20
pubmed: 23408053
Br J Cancer. 2014 Jan 21;110(2):489-500
pubmed: 24169344
Cell Host Microbe. 2014 Mar 12;15(3):266-82
pubmed: 24629334
Nat Rev Clin Oncol. 2014 Sep;11(9):509-24
pubmed: 25001465
Clin Cancer Res. 2015 Feb 15;21(4):781-94
pubmed: 25501579
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Immunity. 2015 Mar 17;42(3):524-37
pubmed: 25769612
Cancer Immunol Res. 2015 Sep;3(9):1042-51
pubmed: 25888578
Cancer Gene Ther. 2015 Sep;22(9):454-62
pubmed: 26337747
Lancet. 2015 Nov 21;386(10008):2078-2088
pubmed: 26386540
Nature. 2016 Jun 01;534(7607):396-401
pubmed: 27281205
Cell Rep. 2016 Jun 21;15(12):2756-70
pubmed: 27292648
J Immunother Cancer. 2016 Oct 18;4:68
pubmed: 27777777
Methods Mol Biol. 2017;1499:223-236
pubmed: 27987153
Neurosci Lett. 2017 Apr 3;645:106-112
pubmed: 28259657
Nat Commun. 2017 May 24;8:15221
pubmed: 28537262
Clin Cancer Res. 2018 Feb 1;24(3):634-647
pubmed: 29018052
Cancer. 2018 Jan 1;124(1):203-211
pubmed: 29105738
Cell. 2018 Dec 13;175(7):1744-1755.e15
pubmed: 30503208
Eur J Immunol. 1993 Sep;23(9):2242-9
pubmed: 7690326
Cancer Res. 1996 Jan 1;56(1):21-6
pubmed: 8548765